BCG Vaccine Could Reduce Dementia Symptoms in Mice
Johns Hopkins researchers found the vaccine may help clear brain plaques and tangles in a mouse model of Alzheimer's.
Updated on Oct. 21, 2026 in Alzheimer’s
Live Poll
Do you believe existing vaccines should be prioritized for their potential off-target health benefits?
Johns Hopkins University researchers found that the BCG vaccine reduces dementia indicators in mice by promoting immune system responses that clear brain proteins. These preliminary findings build on previous human observations regarding vaccine-linked dementia risk reduction.
Why it matters
Understanding how certain vaccines may trigger immune processes that protect the brain offers a new avenue for exploring dementia prevention. This research provides a biological mechanism that may help explain previous human studies linking vaccinations to lower dementia risk.
In a preclinical study published in Science Advances, researchers found that the BCG vaccine normalized 707 of 716 Alzheimer's-related genes in PS19 mice. While these results show a 5-fold reduction in tau deposits, human clinical trials are still required to confirm the findings.
The players
Johns Hopkins University School of Medicine
A prominent research institution known for clinical advancements in neurology and immunology.
The details
The BCG vaccine works by triggering 'trained immunity,' a process where innate immune cells undergo epigenetic and metabolomic reprogramming. Once trained, these myeloid cells become more efficient at identifying and clearing harmful brain plaques and tangles, effectively curbing the inflammation associated with Alzheimer's disease progression.
Timeline
Three months of age was when the mice received the BCG vaccine.
Eight to nine months after vaccination was the time of assessment for disease indicators.
Three to 15 years is the timeframe researchers have observed human dementia risk reduction linked to BCG.
Health Landscape
This research contributes to the emerging field of vaccine-based trained immunity, which explores how non-specific immune activation can offer protective effects against non-infectious conditions. It follows a growing body of evidence, including studies on shingles vaccines, suggesting that established immunizations might influence long-term cognitive health.
These findings are strictly preclinical and do not currently change clinical practice or vaccine recommendations. Anyone interested in the relationship between vaccinations and long-term cognitive health should discuss ongoing research and preventative strategies with their physician.
The takeaway
While the BCG vaccine shows promise in mouse models for clearing proteins linked to Alzheimer's, it is not currently a treatment for humans. Keep track of large-scale clinical trials in the coming years and maintain a conversation with your doctor about established, evidence-based brain health.
Further reading
Learn more about the latest research in this field at the Alzheimer’s section.
Live Poll
Do you believe existing vaccines should be prioritized for their potential off-target health benefits?
